Richard Riedel

Overview:

Novel therapies for soft tissue and bone sarcomas

Positions:

Associate Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2000

Thomas Jefferson University

Resident in Medicine, Medicine

Duke University

Fellow in Hematology-Oncology, Medicine

Duke University

Fellow in Hematology-Oncology, Medicine

Duke University

Grants:

BLU-285-1303

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Dissecting Mechanisms of Metastasis Through Comparative Systems Genetics

Administered By
Radiation Oncology
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date

NIR-DT-301 -1702

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

DCC-2618-03-002 (Intrigue)

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

IMDZ-04-1702

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology.

Authors
Haddox, CL; Riedel, RF
MLA Citation
Haddox, Candace L., and Richard F. Riedel. “Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology..” Expert Rev Anticancer Ther, Dec. 2019, pp. 1–4. Pubmed, doi:10.1080/14737140.2020.1708198.
URI
https://scholars.duke.edu/individual/pub1425021
PMID
31859537
Source
pubmed
Published In
Expert Rev Anticancer Ther
Published Date
Start Page
1
End Page
4
DOI
10.1080/14737140.2020.1708198

Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread.

Myxopapillary ependymomas are a slow-growing, grade I type glial tumor in the lumbosacral region. More rarely, they can present as extradural, subcutaneous sacrococcygeal, or perisacral masses, and it is under these circumstances that they are more likely to spread. Here, we report the presentation of a sacrococcygeal mass in patient that was initially resected confirming extradural myxopapillary ependymoma. At initial resection, multiple small pulmonary nodules were detected. This mass recurred 2 years later at the resection site with an interval increase in the previously imaged pulmonary nodules. Resection of both the post-sacral mass and largest lung metastasis confirmed recurrent myxopapillary ependymoma with oligometastatic spread. Because these tumors are rare, with extradural presentation being even more infrequent, to this date there are no definitive therapeutic guidelines for initial treatment and continued surveillance. For myxopapillary ependymoma, current standard of care is first-line maximal surgical resection with or without postoperative radiotherapy depending on the extent of disease and extent of resection. However, there remains insufficient evidence on the role of radiotherapy to oligometastatic foci in providing any further survival benefit or extending time to recurrence. Thus, prospective studies assessing the role of upfront treatment of oligometastases with local resection and adjuvant radiotherapy are needed for improved understanding of extradural myxopapillary ependymoma.
Authors
Batich, KA; Riedel, RF; Kirkpatrick, JP; Tong, BC; Eward, WC; Tan, CL; Pittman, PD; McLendon, RE; Peters, KB
MLA Citation
Batich, Kristen A., et al. “Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread..” Front Oncol, vol. 9, 2019. Pubmed, doi:10.3389/fonc.2019.01322.
URI
https://scholars.duke.edu/individual/pub1424463
PMID
31850213
Source
pubmed
Published In
Frontiers in Oncology
Volume
9
Published Date
Start Page
1322
DOI
10.3389/fonc.2019.01322

Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.

Authors
Burgess, MA; Bolejack, V; Schuetze, S; Van Tine, BA; Attia, S; Riedel, RF; Hu, JS; Davis, LE; Okuno, SH; Priebat, DA; Movva, S; Reed, DR; D'Angelo, SP; Lazar, AJ; Keung, EZ-Y; Reinke, DK; Baker, LH; Maki, RG; Patel, S; Tawbi, HA-H
MLA Citation
URI
https://scholars.duke.edu/individual/pub1415104
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date

A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1(+) soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.

Authors
Chawla, SP; Van Tine, BA; Pollack, S; Ganjoo, KN; Elias, AD; Riedel, RF; Attia, S; Choy, E; Okuno, SH; Agulnik, M; von Mehren, M; Livingston, MB; Keedy, VL; Verschraegen, CF; Philip, T; Bohac, GC; Yurasov, S; Lu, H; Chen, M; Maki, RG
MLA Citation
URI
https://scholars.duke.edu/individual/pub1415473
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date

ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.

Authors
Wagner, AJ; Ravi, V; Ganjoo, KN; Van Tine, BA; Riedel, RF; Chugh, R; Cranmer, LD; Gordon, EM; Hornick, JL; Kwiatkowski, DJ; Du, H; Grigorian, B; Schmid, AN; Hou, S; Harris, K; Desai, N; Dickson, MA
URI
https://scholars.duke.edu/individual/pub1415500
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
37
Published Date